Abstract: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.
Type:
Grant
Filed:
July 30, 2014
Date of Patent:
January 31, 2017
Assignees:
KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP., KR BIOTECH CO., LTD.
Inventors:
Young-Bong Kim, Hee Jung Lee, Nuri Park, Yu-Kyoung Oh
Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.
Type:
Grant
Filed:
August 31, 2012
Date of Patent:
January 24, 2017
Assignee:
Ceva Sante Animale
Inventors:
Zoltan Penzes, Anna Kollar, Marianna Ivok
Abstract: The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
January 3, 2017
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Kim Burgard, Jeremy Kroll, Sarah M. Layton, Volker Ohlinger, Francois-Xavier Orveillon, Stefan Pesch, Michael Dennis Piontkowski, Michael B. Roof, Philip Utley, Eric Martin Vaughn
Abstract: The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow deposited into ATCC as frozen allantoic fluid (deposit PTA-13024) and as lyophilized form (deposit PTA-121432) is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses.
Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.
Type:
Grant
Filed:
July 25, 2014
Date of Patent:
December 13, 2016
Assignee:
TAKEDA VACCINES, INC.
Inventors:
Charles Richardson, Robert F. Bargatze, Joel Haynes, Bryan Steadman
Abstract: This invention relates to formulations which contain at least one active peptide intended to be used for prevention or treatment of a condition in an animal or human. Said active peptide has been expressed in a system that improves the conservation of those properties essential to the prophylactic or therapeutic effect of said peptide before and after delivery to an animal or human and until the peptide delivers its activity at the effector site within said animal or human. The invention is particularly relevant to formulations of oral or mucosal vaccines or biopharmaceuticals. The active peptide of the formulation is recombinantly expressed in cells or whole animals. In a preferred embodiment of this invention the active polypeptide of the formulation has been recombinantly expressed in insect cells or whole insect larvae.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
November 8, 2016
Assignee:
BIOORGANIC RESEARCH AND SERVICES SA
Inventors:
Victor Infante, Juan Jose Infante, Kevin O'Connor, David Cotan
Abstract: Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.
Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
Type:
Grant
Filed:
January 28, 2014
Date of Patent:
October 11, 2016
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Mahidol University
Inventors:
Richard M. Kinney, Claire Y. H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
Type:
Grant
Filed:
January 24, 2014
Date of Patent:
September 13, 2016
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Inventors:
Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
Abstract: Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Type:
Grant
Filed:
April 29, 2008
Date of Patent:
August 30, 2016
Assignees:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
Abstract: The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition.
Abstract: The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.
Type:
Grant
Filed:
October 26, 2012
Date of Patent:
August 2, 2016
Assignee:
INTERNATIONAL AIDS VACCINE INITIATIVE
Inventors:
C. R. King, Michael J. Caulfield, Ivo C. Lorenz, Christopher L. Parks
Abstract: The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.
Type:
Grant
Filed:
November 25, 2011
Date of Patent:
August 2, 2016
Assignees:
INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUEST
Inventors:
Marc Eloit, Justine Cheval, Virginie Sauvage
Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.
Type:
Grant
Filed:
October 4, 2010
Date of Patent:
July 19, 2016
Assignees:
The National Veterinary Institute, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
W. Ian Lipkin, Gustavo Palacios, Ruth T. Kongtorp, Edgar Brun
Abstract: The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.
Type:
Grant
Filed:
April 14, 2014
Date of Patent:
July 5, 2016
Assignee:
Novavax, Inc.
Inventors:
Gale Smith, Peter Pushko, Kutub Mahmood, Bin Zhou
Abstract: The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.
Type:
Grant
Filed:
May 28, 2013
Date of Patent:
June 14, 2016
Assignee:
Oncolytics Biotech Inc.
Inventors:
Donald Morris, Bradley G. Thompson, Matthew C. Coffey
Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
Type:
Grant
Filed:
April 29, 2008
Date of Patent:
June 14, 2016
Assignees:
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University